| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 0.72 [0.57, 0.90] | | < 1 | | 0% | 15 studies (15/-) | 99.8 % | some concern | low | moderate | crucial | - |
| death or transfer to ICU | 0.89 [0.59, 1.34] | | < 1 | | 46% | 2 studies (2/-) | 71.8 % | high | not evaluable | low | crucial | - |
| deaths | 0.78 [0.68, 0.91] | | < 1 | | 0% | 43 studies (43/-) | 100.0 % | some concern | critical | moderate | crucial | - |
| deaths (time to event analysis only) | 0.68 [0.43, 1.08] | | < 1 | | 0% | 4 studies (4/-) | 95.0 % | some concern | not evaluable | moderate | crucial | - |
| clinical deterioration | 0.71 [0.52, 0.98] | | < 1 | | 63% | 18 studies (18/-) | 98.2 % | some concern | low | moderate | important | - |
| clinical improvement | 1.23 [1.01, 1.50] | | > 1 | | 62% | 17 studies (17/-) | 98.1 % | some concern | low | moderate | important | - |
| clinical improvement (14-day) | 1.22 [1.00, 1.49] | | > 1 | | 32% | 10 studies (10/-) | 97.6 % | some concern | low | moderate | important | - |
| clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
| clinical improvement (28-day) | 1.34 [1.10, 1.62] | | > 1 | | 46% | 5 studies (5/-) | 99.8 % | some concern | serious | moderate | important | - |
| clinical improvement (7-day) | 1.25 [1.02, 1.55] | | > 1 | | 64% | 11 studies (11/-) | 98.2 % | some concern | critical | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.17 [0.99, 1.39] | | > 1 | | 67% | 12 studies (12/-) | 97.1 % | some concern | critical | moderate | important | - |
| death or ventilation | 0.75 [0.63, 0.88] | | < 1 | | 0% | 5 studies (5/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| hospital discharge | 1.21 [0.97, 1.51] | | > 1 | | 46% | 7 studies (7/-) | 95.6 % | some concern | serious | moderate | important | - |
| hospitalization | 0.46 [0.06, 3.45] | | < 1 | | 28% | 2 studies (2/-) | 77.4 % | low | not evaluable | high | important | - |
| mechanical ventilation | 0.97 [0.71, 1.34] | | < 1 | | 22% | 16 studies (16/-) | 56.3 % | some concern | critical | moderate | important | - |
| mechanical ventilation (time to event analysis only) | 0.06 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | important | - |
| radiologic improvement (14-day) | 1.82 [0.95, 3.51] | | > 1 | | 39% | 4 studies (4/-) | 96.4 % | some concern | not evaluable | moderate | important | - |
| radiologic improvement (7-day) | 0.98 [0.09, 10.24] | | > 1 | | 72% | 4 studies (4/-) | 49.3 % | some concern | not evaluable | moderate | important | - |
| viral clearance | 1.50 [1.14, 1.96] | | > 1 | | 70% | 19 studies (19/-) | 99.8 % | some concern | critical | moderate | important | - |
| viral clearance (time to event analysis only) | 1.23 [0.87, 1.74] | | > 1 | | 74% | 7 studies (7/-) | 87.6 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 14 | 1.04 [0.23, 4.74] | | > 1 | | 93% | 10 studies (10/-) | 51.9 % | some concern | low | moderate | important | - |
| viral clearance by day 7 | 1.33 [1.05, 1.68] | | > 1 | | 67% | 15 studies (15/-) | 99.1 % | some concern | critical | moderate | important | - |
| ICU admission | 0.99 [0.75, 1.30] | | < 1 | | 0% | 9 studies (9/-) | 53.1 % | some concern | not evaluable | moderate | non important | - |
| recovery | 1.01 [0.82, 1.25] | | > 1 | | 56% | 4 studies (4/-) | 54.1 % | some concern | not evaluable | moderate | non important | - |
| severe COVID-19 occurrence | 0.30 [0.07, 1.27] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| serious adverse events | 0.74 [0.53, 1.02] | | < 1 | | 0% | 17 studies (17/-) | 96.6 % | some concern | low | moderate | important | - |
| acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
| adverse events | 1.84 [1.36, 2.49] | | < 1 | | 63% | 21 studies (21/-) | 0.0 % | some concern | low | moderate | non important | - |
| arrhythmia | 2.24 [0.23, 21.69] | | < 1 | | 0% | 1 study (1/-) | 24.5 % | NA | not evaluable | | non important | - |
| elevated liver enzymes | 3.48 [1.40, 8.64] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| long QT | 9.79 [1.27, 75.50] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
| Major bleeding | 1.80 [0.88, 3.67] | | < 1 | | 0% | 1 study (1/-) | 5.3 % | NA | not evaluable | | non important | - |
| renal impairment | 1.35 [0.47, 3.86] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
| serious adverse events (SAE), any | 0.50 [0.32, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
AE of interest endpoints 00 |
| Thromboembolic events | 0.89 [0.31, 2.55] | | < 1 | | 0% | 1 study (1/-) | 58.6 % | NA | not evaluable | | non important | - |
